Janux Therapeutics CEO David Campbell is selling $1.4 million worth of stock to Investing.com
David Alan Campbell, President and CEO of Janux Therapeutics, Inc. (NASDAQ:JANX), recently sold 25,000 shares of the company’s stock. The transaction, which occurred on December 24, 2024, was executed pursuant to a trading plan pursuant to Rule 10b5-1. The shares were sold at a weighted average price of $56.1922, resulting in a total transaction value of approximately $1.4 million. After the sale, Campbell retains ownership of 217,054 shares in the company, representing a significant stake in the $2.9 billion biotech company. This insider transaction comes amid an extraordinary year for Janux, with shares up 404% year-to-date. – date according to InvestingPro data. While the stock is currently trading above its estimated fair value, analysts maintain price targets in the $25-$200 range, reflecting the volatile nature of biotech investing. InvestingPro subscribers can access 13 additional investment tips and comprehensive financial indicators for in-depth analysis.
In other recent news, Janux Therapeutics is receiving positive attention from several analyst firms. Clear Street initiated coverage on Janux Therapeutics, assigning a Buy rating and setting a $80 price target, citing optimism about the company’s prospects in the oncology market. Scotiabank (TSX: ) also adjusted its outlook on Janux, raising its price target to $62, while maintaining its sector perform rating. This follows the release of promising Phase 1 trial results for Janux’s lead drug candidate, JANX007.
Jones Trading revised its target on Janux Therapeutics to $105, reflecting confidence in the treatment’s potential to be used in earlier lines of therapy. TD Cowen maintained a positive outlook on Janux, reiterating a Buy rating. The company highlighted the impressive prostate-specific antigen reduction rates of Janux’s ‘007 candidate. Stifel raised its price target on Janux to $115, maintaining a Buy rating, following promising clinical data from the ‘007 candidate.
These recent developments highlight the potential of Janux’s drug candidates, particularly JANX007, in the oncology market. The company expects the key data readings, projected for 2025, to potentially put Janux in an advantageous position in the oncology drug market. The ongoing trial and its results are critical for Janux Therapeutics as it navigates the competitive landscape of cancer treatment development.
This article was generated with the help of AI and reviewed by an editor. See our T&C for more information.
